Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

KPRX

Kiora Pharmaceuticals Inc

Dec 13 • 04:00PM ET

3.32

Dollar change -0.19
Percentage change -5.47	%

Healthcare • Biotechnology • USA • NASD

Peers: ARWR RGEN EYPT OCUL CLSD ALDX PRQR IRD VSTM PULM

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.54	Insider Own	6.72%	Shs Outstand	3.00M	Perf Week	-5.14%
Market Cap	9.42M	Forward P/E	-	EPS next Y	-2.40	Insider Trans	7.48%	Shs Float	2.80M	Perf Month	-3.49%
Income	5.55M	PEG	-	EPS next Q	-0.60	Inst Own	54.98%	Short Float	1.50%	Perf Quarter	-2.64%
Sales	16.02M	P/S	0.59	EPS this Y	103.07%	Inst Trans	57.03%	Short Ratio	1.65	Perf Half Y	-38.06%
Book/sh	10.01	P/B	0.33	EPS next Y	-422.42%	ROA	20.40%	Short Interest	0.04M	Perf Year	-35.85%
Cash/sh	10.24	P/C	0.32	EPS next 5Y	-	ROE	29.11%	52W Range	3.00 - 8.98	Perf YTD	-29.39%
Dividend Est.	-	P/FCF	1.15	EPS past 5Y	56.98%	ROI	18.46%	52W High	-63.04%	Beta	-0.49
Dividend TTM	-	Quick Ratio	8.97	Sales past 5Y	-27.40%	Gross Margin	99.65%	52W Low	10.67%	ATR (14)	0.20
Dividend Ex-Date	-	Current Ratio	8.97	EPS Y/Y TTM	101.84%	Oper. Margin	38.05%	RSI (14)	44.15	Volatility	5.01% 5.62%
Employees	12	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	34.64%	Recom	1.00	Target Price	30.33
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	89.84%	Payout	-	Rel Volume	1.21	Prev Close	3.51
Sales Surprise	-100.00%	EPS Surprise	-6.12%	Sales Q/Q	-	Earnings	Nov 08 BMO	Avg Volume	25.55K	Price	3.32
SMA20	-2.70%	SMA50	-4.36%	SMA200	-21.12%	Trades		Volume	30,889	Change	-5.47%

Nov-08-24 07:00AM	Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies (Newsfile)
Oct-30-24 07:28AM	Kiora Pharmaceuticals Gains Approval for Phase 2 Trial (TipRanks)
Oct-29-24 06:45AM	Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa (Newsfile)
Sep-25-24 09:55AM	Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences (Newsfile)
Aug-09-24 02:53PM	KPRX Stock Earnings: Kiora Pharmaceuticals Beats EPS for Q2 2024 (InvestorPlace)
07:00AM	Loading…
07:00AM	Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies (Newsfile)
Aug-06-24 07:03AM	Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences (Newsfile)
Jul-30-24 06:45AM	Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies (Newsfile)
Jul-10-24 07:00AM	Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation (Newsfile)
Jul-01-24 06:54AM	Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors (Newsfile)
Jun-25-24 06:45AM	Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board (Newsfile)
Jun-18-24 09:40AM	Is Kiora Pharmaceuticals (KPRX) Stock Undervalued Right Now? (Zacks)
May-29-24 06:44PM	Lytham Partners Spring 2024 Investor Conference Starts Tomorrow, May 30, 2024 (Newsfile) -6.36%
May-20-24 07:00AM	Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences (Newsfile)
May-10-24 01:54PM	KPRX Stock Earnings: Kiora Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
07:00AM	Loading…
07:00AM	Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease (Newsfile)
May-08-24 07:00AM	Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference (Newsfile)
May-06-24 07:00AM	Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients with Retinitis Pigmentosa (Newsfile)
Apr-11-24 07:00AM	Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study (Newsfile)
Apr-05-24 07:00AM	Kiora Pharmaceuticals to Present at Upcoming Investor Conferences (Newsfile)
Mar-28-24 06:45AM	Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting (Newsfile) +14.41%
Mar-25-24 07:00AM	Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases (Newsfile)
Mar-08-24 07:00AM	Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye (Newsfile)
Feb-01-24 08:14AM	Why Is Kiora Pharmaceuticals (KPRX) Stock Up 39% Today? (InvestorPlace) +53.87%
Jan-31-24 06:40PM	Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million (Newsfile) -6.20%
05:15PM	Kiora Pharmaceuticals and Th a Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clinical Development, Regulatory and Commercial Milestones, Plus Commercial Royalties (Newsfile)
Nov-17-23 01:54PM	Breaking ground in vision restoration: Kiora Pharmaceuticals reveals promising results with KIO-301 (News Direct)
Nov-09-23 07:18AM	Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa (Newsfile)
Nov-04-23 12:15PM	AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa (Newsfile)
Oct-16-23 07:00AM	Kiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor Conference (Newsfile) -5.30%
07:00AM	Loading…
Oct-03-23 07:00AM	Kiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis Pigmentosa (Newsfile)
Sep-21-23 07:00AM	Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years (Newsfile)
Sep-18-23 07:00AM	Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis Pigmentosa (Newsfile)
Sep-14-23 07:01AM	Kiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis Pigmentosa (Newsfile)
Sep-01-23 07:00AM	Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27 (Newsfile)
Aug-29-23 01:43PM	Kiora Pharmaceuticals and the Choroideremia Research Foundation to Host Webinar on the Development of Molecular Photoswitches for Inherited Retinal Diseases (Newsfile)
Aug-23-23 07:33PM	Is Kiora Pharmaceuticals Significantly Undervalued? A Comprehensive Valuation Analysis (GuruFocus.com) +22.55% -16.80%
07:00AM	Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious Uveitis (Newsfile)
Aug-22-23 01:06PM	Kiora Pharmaceuticals Taps B2i Digital to Deploy Data-Driven Investor Awareness Program (Newsfile)
Aug-16-23 07:00AM	Kiora Pharmaceuticals Webcasts Its Investor Presentation from the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference (Newsfile)
Aug-08-23 07:00AM	Kiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress (Newsfile)
Aug-03-23 07:00AM	Kiora Pharmaceuticals, Inc. and Choroideremia Research Foundation Partner to Advance Novel Choroideremia Treatment (Newsfile)
Aug-01-23 07:00AM	Biotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of Directors (Newsfile)
Jul-05-23 07:00AM	Kiora Pharmaceuticals Receives $1.2 Million in Research Tax Credits to Advance the Treatment of Ophthalmic Disease (Newsfile)
Jun-23-23 08:35AM	Life Science Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire) -6.57%
Jun-20-23 10:58AM	Life Science Investor Forum Agenda Announced for June 22nd (GlobeNewswire) -7.68%
Jun-15-23 07:00AM	Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201 (Newsfile) +5.49%
Jun-14-23 08:00AM	Kiora Pharmaceuticals to Present at Upcoming Investor Conferences (Newsfile)
Jun-06-23 04:30PM	Kiora Pharmaceuticals Announces Closing of $6.3 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option (Newsfile) -7.53%
Jun-02-23 08:30AM	Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering (Newsfile) -49.55%
May-09-23 07:00AM	Kiora Pharmaceuticals Reports First Quarter Results; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments (Newsfile)
May-01-23 07:00AM	Kiora Pharmaceuticals Presents Encore Imaging Results of KIO-301 for Retinitis Pigmentosa at ASNR 2023 Meeting (Newsfile) -10.36%
Apr-27-23 02:55PM	Kiora's Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in Patients Who Are Blind (Newsfile) +8.90%
Apr-26-23 07:00AM	Kiora Pharmaceuticals' KIO-201 Heals Wounds in Phase 2 Trial of Patients with Persistent Corneal Epithelial Defects (Newsfile) +6.98%
Apr-21-23 07:00AM	Inherited Retinal Disease Expert, Mark Pennesi, M.D., Ph.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board (Newsfile) +14.49%
Apr-17-23 07:00AM	Kiora Pharmaceuticals Initiates Phase 2 Trial of KIO-101 for the Treatment of Ocular Presentation of Autoimmune Diseases (Newsfile)
Mar-30-23 07:00AM	Kiora Announces the Acceptance of Late-Breaking Abstract on Phase 1b Study of KIO-301 in Retinitis Pigmentosa at The American Society of Neuroradiology 2023 Meeting (Newsfile)
Mar-23-23 07:00AM	Kiora Pharmaceuticals Reports 2022 Financial Results; Provides Update on Clinical Development Progress (Newsfile) -9.37%
Mar-10-23 07:00AM	Kiora Pharmaceuticals Announces the Acceptance of Three Abstracts at the 2023 ARVO Annual Meeting (Newsfile)
Feb-09-23 12:00PM	Biotech Stock Roundup: AMGN, GILD, BMY, REGN's Q4 Results, KPRX Up on Study Update (Zacks)
Feb-07-23 08:00AM	Kioras stock rallies as eye drop treatment moves into mid-stage clinical trial (MarketWatch) +38.72%
07:00AM	Kiora Pharmaceuticals Receives Investigational New Drug Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases (Newsfile)
Feb-03-23 07:00AM	Kiora Pharmaceuticals Enters into Two Equity Purchase Agreements with Lincoln Park Capital (Newsfile)
Jan-09-23 07:00AM	Kiora Pharmaceuticals Highlights Anticipated Clinical and Corporate Milestones for 2023; Webcast Now Available on Company Website (Newsfile)
Jan-03-23 07:01AM	Kiora Pharmaceuticals Completes Enrollment of Clinical Trial Evaluating KIO-201 for Persistent Corneal Epithelial Defects; Results Expected to be Reported in 1H 2023 (Newsfile)
Dec-14-22 08:19AM	Stonegate Healthcare Reviews Retinitis Pigmentosa (Newsfile)
Nov-18-22 08:30AM	Kiora Pharmaceuticals Enters Into Agreements to Raise $3.12 Million From the Exercise of Previously Issued Class A Warrants (Newsfile) -35.85%
Nov-17-22 06:45AM	Kiora Pharmaceuticals Doses First Patient in ABACUS Phase 1b Study Evaluating KIO-301 for Retinitis Pigmentosa (Newsfile)
Nov-09-22 06:45AM	Kiora Pharmaceuticals Provides 3rd Quarter 2022 Business and Financial Update; Dosing of KIO-301 in Phase 1 Trial for Retinitis Pigmentosa to Begin Before Year's End (Newsfile) -5.76%
Oct-31-22 08:01AM	KOL Webinar on Genetic Blindness Points to Promise of Kioras Pioneering Solution--Clinical Data in Q1 (News Direct)
Oct-17-22 08:00AM	Kiora Pharmaceuticals Announces Publication of Phase 1 Trial Results for KIO-100 as a Treatment for Ocular Inflammatory Disease (Newsfile)
Oct-13-22 06:45AM	Kiora Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements (Newsfile)
Sep-28-22 11:44AM	Battling Blindness: Virtual Investor Event on Treatments for Retinitis Pigmentosa to Be Held October 19; Panelists include Kiora Pharmaceuticals, Foundation Fighting Blindness, and Retinal Surgeon Christine Kay, M.D. (Newsfile) +6.06%
Sep-26-22 06:45AM	Kiora Pharmaceuticals to Implement 1-for-40 Reverse Split (Newsfile) -10.05%
Sep-13-22 06:45AM	Kiora Pharmaceuticals Appoints Melissa Tosca as Executive Vice President of Finance (Newsfile) +21.00%
Aug-15-22 06:30AM	KPRX: What a difference a year makes! (Zacks Small Cap Research)
Aug-12-22 06:45AM	Kiora Pharmaceuticals Reports First Half 2022 Business Update and Financial Results (Newsfile) -10.71%
Jul-28-22 06:45AM	Kiora Pharmaceuticals Issued US Patent Covering KIO-201 Technology in Combination with Antibiotics (Newsfile)
Jul-26-22 04:38PM	Kiora Pharmaceuticals Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option (Newsfile)
Jul-22-22 08:30AM	Kiora Pharmaceuticals Announces Pricing of $5.2 Million Underwritten Public Offering (Newsfile) -39.76%
Jul-05-22 06:45AM	Kiora Pharmaceuticals Announces First Patient Enrolled in Phase 2 Study Evaluating KIO-201 for Persistent Corneal Epithelial Defects (Newsfile)
Jun-27-22 06:53AM	Kiora Pharmaceuticals Receives Clinical Trial Approval for First-in-Human Evaluation of KIO-301 to Restore Vision in Patients with Retinitis Pigmentosa (Newsfile)
May-31-22 04:30PM	Kiora Pharmaceuticals Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1) (Newsfile) +10.00% -5.41%
Apr-25-22 06:45AM	Kiora Pharmaceuticals Announces Presentation of KIO-101 Clinical Trial Data at the American Society of Cataract and Refractive Surgery 2022 (Newsfile)
Apr-15-22 09:00AM	Kiora Pharmaceuticals Reports 2021 Results and Provides Business Update (Newsfile)
Mar-21-22 06:45AM	Kiora Pharmaceuticals to Participate in Maxim Group's 2022 Virtual Growth Conference March 28th - 30th (Newsfile)
Mar-18-22 12:00PM	Kiora Pharma Snags Orphan Drug Tag For Inherited Genetic Eye Disease Candidate (Benzinga) -7.09%
06:45AM	Kiora Pharmaceuticals Granted Orphan Drug Designation for KIO-301, an Investigational Drug for the Treatment of Retinitis Pigmentosa (RP) (Newsfile)
Feb-08-22 06:45AM	Kiora Pharmaceuticals Announces Participation at 2022 BIO CEO & Investor Conference (Newsfile)
Feb-01-22 06:45AM	Kiora Pharmaceuticals Appoints Erin Parsons to its Board of Directors; Stephen From to Retire from Board (Newsfile)
Jan-05-22 07:00AM	Kiora Pharmaceuticals to Provide 2022 Business Outlook at the H.C. Wainwright Bioconnect Virtual Conference (Newsfile) -7.96%
Dec-15-21 07:00AM	Kiora Pharmaceuticals Appoints David Hollander, MD, MBA, to its Board of Directors (Newsfile) -27.02%
Dec-14-21 07:15AM	Kiora Reports KIO-101 is Safe and Tolerable; Topline Data Supports Advancing KIO-101 to a Phase 2 Study in Patients with Dry Eye Disease (Newsfile) -8.89%
Nov-15-21 07:30AM	Kiora Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)

Kiora Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102. The company was founded in 1998 and is headquartered in Encinitas, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Stengone Carmine N.	Director	Sep 11 '24	Buy	3.68	1,250	4,600	1,250	Sep 12 06:32 AM
Shapiro Aron	Director	Sep 10 '24	Buy	3.60	3,000	10,800	3,000	Sep 11 07:02 AM
Walters-Hoffert Lisa	Director	Aug 19 '24	Buy	3.86	1,250	4,825	1,250	Aug 20 01:00 PM
TYLE PRAVEEN	Director	Aug 19 '24	Buy	3.96	5,000	19,800	5,014	Aug 19 03:45 PM
Tosca Melissa	CFO	Aug 14 '24	Buy	3.21	2,000	6,420	13,599	Aug 15 04:17 PM
Tosca Melissa	EVP Finance	Jun 14 '24	Buy	5.25	100	525	3,979	Jun 14 04:47 PM
Daniels Eric Joseph	Chief Development Officer	Jun 14 '24	Buy	5.29	1,431	7,570	11,222	Jun 14 03:40 PM
Parsons Erin	Director	Jun 13 '24	Buy	4.88	5,260	25,669	5,260	Jun 13 03:51 PM
Strem Brian M.	President and CEO	Jun 13 '24	Buy	5.00	3,000	14,997	14,531	Jun 13 03:49 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KPRX

Kiora Pharmaceuticals Inc

Upgrade your FINVIZ experience